LiqMeds Group will be acquired by Zydus Life for Rs 689 crore
Zydus said, "LiqMeds Group presently commercializes its products through partners, and it has the capacity and expertise to develop, manufacture, and supply oral liquid products for global markets."
The board of Indian pharmaceutical giant Zydus Lifescienes has approved the purchase of oral liquid products manufacturer LiqMeds for a sum of Rs 689 crore.
Exchanges were notified by the firm on October 31 that Zydus UK will purchase the whole business. It is anticipated that the purchase will be completed ten working days after the execution date.
According to the firm, liquid orals represent a sizable and expanding industry that presents Zydus with considerable new market growth prospects and unmet demands.
Zydus said that it feels oral liquid formulations will benefit pediatric and geriatric patients, bringing in more ease of comfort and therapeutic compliance, in keeping with its patient-centric strategy.
Zydus said, "LiqMeds Group presently commercializes its products through partners, and it has the capacity and expertise to develop, manufacture, and supply oral liquid products for global markets."
No comments:
Post a Comment